Efficient Synthesis of Antisense Phosphorothioate Oligonucleotides: Evaluation of Dichloroacetic Acid at Higher Concentration to Reduce Cycle Time

Organic Process Research and Development

Volumn 7, Issue 6, 2003, Pages 917-920

  Cheruvallath, Zacharia S ^a   Carty, Recaldo L ^a   Andrade, Mark ^a   Moore, Max N ^a   Song, Quinlai ^a   Rentel, Claus ^a   Cole, Douglas L ^a   Ravikumar, Vasulinga T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE PHOSPHOROTHIOATE OLIGONUCLEOTIDE; DICHLOROACETIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); DETRITYLATION; SYNTHESIS;

EID: 0347996086     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op030006j     Document Type: Article

References (52)

1. Beaucage, S. L.; Iyer, R. P. Tetrahedron 1992, 24, 2223 and references therein.
2. Srivatsa, G. S.; Ravikumar, V. T.; Scozzari, A. N.; Cole, D. L. Special Issues for Synthetic Antisense Oligonucleotides. In Biopharmaceutical Process Validation; Sofer, G., Zabriskie, D. W., Eds.; Marcel Dekker: New York, 2000; Chapter 16, pp 309-327.
3. Ravikumar, V. T.; Andrade, M.; Wyrzykiewicz, T. K.; Scozzari, A. N.; Cole, D. L. Nucleosides Nucleotides 1995, 14, 1219.
4. Iyer, R. P.; Beaucage, S. L. In Comprehensive Natural Product Chemistry; Barton, D. H. R., Nakanishi, K., Eds.; DNA and Aspects of Molecular Biology, Vol. 7; Kool, E. T., Vol. Ed.; Pergamon Press: Elmsford, NY, 1999; p 105.
5. Cole, D. L. in Large-scale synthesis of therapeutic antisense oligonucleotides: cost reduction and manufacturing scale-up. International Round Table Conference 1996, La Jolla, CA.
6. Scozzari, A. N. Large Scale Oligonucleotide Synthesis: Production, Purification and Analysis; IBC Conference, October 28-29, 1997, San Diego, CA.
7. Geiser, T. Ann. N.Y. Acad. Sci. 1990, 616, 173.
8. Atkinson, T.; Smith, M. In Solid-phase Synthesis of Oligodeoxyribonucleotides by the Phosphite-Triester Method in Oligonucleotide Synthesis: A Practical Approach; Gait, M. J., Ed.; IRL Press: NY, 1984.
9. Krotz, A. H.; Cole, D. L.; Ravikumar, V. T. Bioorg. Med. Chem. 1999, 7, 435.
10. Krotz, A. H.; Carty, R. L.; Moore, M. N.; Scozzari, A. N.; Cole, D. L.; Ravikumar, V. T. Green Chem. 1999, 277.
11. Krotz, A. H.; Carty, R. L.; Scozzari, A. N.; Cole, D. L.; Ravikumar, V. T. Org. Process Res. Dev. 2000, 4, 190.
12. Affinitak (ISIS 3521) is targeted to the 3́-untranslated region of PKC-α mRNA selectively inhibiting PKC-α gene expression. This oligonucleotide inhibits the growth of a variety of tumor types in vivo using nude mouse tumor xenografts and sequence-specific antitumor activity supports an antisense mechanism of action in vivo. Clinical evaluation (pivotal Phase III) of this drug in humans as potential treatment for nonsmall cell lung cancer is currently ongoing. Geiger, T.; Muller, M.; Dean, N. M.; Fabbro, D. Anticancer Drug Des. 1998, 13, 35.
13. Cheruvallath, Z. S.; Wheeler, P. D.; Cole, D. L.; Ravikumar, V. T. Nucleosides Nucleotides 1999, 18, 484.
14. Cheruvallath, Z. S.; Carty, R. L.; Moore, M. N.; Capaldi, D. C.; Krotz, A. H.; Wheeler, P. D.; Turney, B. J.; Craig, S. R.; Gaus, H. J.; Scozzari, A. N.; Cole, D. L.; Ravikumar, V. T. Org. Process Res. Dev. 2000, 4, 199.
15. Capaldi, D. C.; Gaus, H.; Krotz, A. H.; Arnold, J.; Carty, R. L.; Moore, M. N.; Scozzari, A. N.; Lowery, K.; Cole, D. L.; Ravikumar, V. T. Org. Process Res. Dev. 2003, 7, 832-838.
16. Experience has taught us that yields expressed in terms of weight/μmole of loaded support are more reliable than those expressed in terms of optical density/μmol.
17. Srivatsa, G. S.; Batt, M.; Schuette, J.; Carlson, R. H.; Fitchett, J.; Lee, C.; Cole, D. L. J. Chromatogr., Sect. A 1994, 680, 469.
18. Srivatsa, G. S.; Klopchin, P.; Batt, M.; Feldman, M.; Carlson, R. H.; Cole, D. L. J. Pharm. Biomed. Anal. 1997, 16, 619.
19. The 91% full-length is typical when the entire DMT-on peak is collected. Much higher purity (∼96-97%% full-length) is easily achieved by efficient fractionation of the DMT-on peak. Fractionation of DMT-on peak results in less than a 5% loss of full-length material.
20. The purified full-length by IP-LC-MS is less than CGE values since the former analytical tool is efficiently able to distinguish and quantify process-related species such as depurinated oligonucleotides that comigrate in CGE.
21. Anderson, W.; Hayes, D. H.; Michelson, A. M.; Todd, A. R. J. Chem. Soc. 1954, 1882.
22. Lehrfeld, J. J. Org. Chem. 1967, 32, 2544.
23. Kovac, P.; Bauer, S. Tetrahedron Lett. 1972, 28, 2349.
24. Letsinger, R. L.; Finnan, J. L. J. Am. Chem. Soc. 1975, 97, 7197.
25. Stawinski, J.; Hozumi, T.; Narang, S. A.; Bahl, C. P.; Wu, R. Nucleic Acids Res. 1977, 4, 353.
26. Takaku, H.; Nomoto, T.; Sakamoto, Y.; Hata, T. Chem. Lett. 1979, 1225.
27. Engels, J. Angew. Chem., Int. Ed. Engl. 1979, 18, 148.
28. Kohli, V.; Blocker, H.; Koster, H. Tetrahedron Lett. 1980, 21, 2683.
29. Matteucci, M. D.; Caruthers, M. H. Tetrahedron Lett. 1980, 21, 3243.
30. Kierzek, R.; Ito, H.; Bhatt, R.; Itakura, K. Tetrahedron Lett. 1981, 22, 3761.
31. Koster, H.; Sinha, N. D. Tetrahedron Lett. 1982, 23, 2641.
32. Chaudhuri, B.; Reese, C. B.; Weclawek, T. Tetrahedron Lett. 1984, 25, 4037.
33. Bessodes, M.; Komiotis, D.; Antonakis, K. Tetrahedron Lett. 1986, 27, 579.
34. Krainer, E.; Naider, F.; Becker, J. Tetrahedron Lett. 1993, 34, 1713.
35. Fuentes, J.; Cuevas, T.; Pradera, M. A. Synth. Commun. 1994, 24, 2237.
36. Sekine, M. Nucleosides Nucleotides 1994, 13, 1397.
37. Patil, S. V.; Mane, R. B.; Salunkhe, M. M. Synth. Commun. 1994, 24, 2423.
38. Leonard, N. J.; Neelima Tetrahedron Lett. 1995, 36, 7833.
39. Hwu, J. R.; Jain, M. L.; Tsay, S. C.; Hakimelahi, G. H. Chem. Commun. 1996, 545.
40. Asakura, J.; Robins, M. J.; Asaka, Y.; Kim, T. H. J. Org. Chem. 1996, 61, 9026.
41. Wang, Y.; McGuigan, C. Synth. Commun. 1997, 27, 3829-3833.
42. Yang, S. G.; Lee, D. H.; Kim, Y. H. Heteroat. Chem. 1997, 8, 435.
43. Wahlstrom, J. L.; Ronald, R. C. J. Org. Chem. 1998, 63, 6021.
44. Lu, R. J.; Liu, D.; Giese, R. W. Tetrahedron Lett. 2000, 41, 2817.
45. Jones, G. B.; Hynd, G.; Wright, J. M.; Sharma, A. J. Org. Chem. 2000, 65, 263.
46. Pathak, A. K.; Pathak, V.; Seitz, L. E.; Tiwari, K. N.; Akhtar, M. S.; Reynolds, R. C. Tetrahedron Lett. 2001, 42, 7755.
47. Reinhardt, L. A.; Sacksteder, K. A.; Cleland, W. W. J. Am. Chem. Soc. 1998, 120, 13366.
48. DPA has viscosity of 1.4540 vs 1.4660 for DCA.
49. Paul, C. H.; Royappa, A. T. Nucleic Acids Res. 1996, 24, 3048.
50. Septak, M. Nucleic Acids Res. 1996, 24, 3053.
51. It was found that 40-60% of total eluted DMT groups are in the "colorless" initial eluent.
52. Ravikumar, V. T.; Krishna Kumar, R.; Capaldi, D. C.; Turney, B.; Rentel, C.; Cole, D. L. Org. Process Res. Dev. 2003, 7, 259.